George Uy

Chief Executive Officer & Founder

George Uy founded TRIGR in April 2018 with over 35 years of pharmaceutical and biotech leadership experience. For over 20 years, George was principally responsible for leading strategic marketing and commercial initiatives across Roche (Manila, Basel and Nutley) including establishing Roche Shanghai Commercial and launching Xeloda® in oncology in the USA . Subsequent to his tenure at Roche, George joined Abraxis Biosciences (formerly Nasdaq: ABRX now CELGENE) where he helped built out the oncology commercial organization and was responsible for all aspect of the launch from pre-marketing to commercialization of Abraxane®. George then served as Senior Vice President of Commercial Operations at Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPM) and most recently, as Chief Commercial Officer Sorrento Therapeutics (Nasdaq: SRNE), where he was instrumental in transitioning the Company from the OTC market to Nasdaq. George holds a Bachelor of Science in Medical Technology from the Cebu Institute of Medicine, Philippines.

Miranda Toledano

Chief Operating Officer & Chief Financial Officer

Ms. Toledano joined TRIGR in 2018 with over 20 years of biotech related Wall Street principal investment, capital market and advisory experience. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) as EVP Corporate Development where she helped drive the Company’s hematology/oncology (IO mAbs, ADC), cellular therapy (CD-38 CAR-T, oncolytic virus) and pain franchises. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she was completed biotech equity financings (IPO, follow-on) totaling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served as a VP in the investment group of Royalty Pharma, where she focused on oncology/hematology and auto-immune monoclonal antibody investments. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.